| Title |
A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis
|
|---|---|
| Published in |
Dermatology and Therapy, December 2015
|
| DOI | 10.1007/s13555-015-0092-3 |
| Pubmed ID | |
| Authors |
Molly Campa, Bobbak Mansouri, Richard Warren, Alan Menter |
| Abstract |
The development of several highly effective biologic drugs in the past decade has revolutionized the treatment of moderate-to-severe plaque psoriasis. With increased understanding of the immunopathogenesis of psoriasis, the emphasis has turned toward more specific targets for psoriasis drugs. Although the complex immunological pathway of psoriasis is not yet completely understood, current models emphasize the significant importance of interleukin (IL)-23 and IL-17. Several biologic drugs targeting these cytokines are now in various stages of drug development. Drugs targeting IL-23 include BI-655066, briakinumab, guselkumab, tildrakizumab, and ustekinumab. Drugs targeting IL-17 include brodalumab, ixekizumab, and secukinumab. While many of these have shown safety and good efficacy in clinical trials of moderate-to-severe plaque psoriasis, long-term safety is still to be established. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Science communicators (journalists, bloggers, editors) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 145 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Colombia | 1 | <1% |
| United States | 1 | <1% |
| Germany | 1 | <1% |
| Unknown | 142 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 27 | 19% |
| Researcher | 24 | 17% |
| Other | 18 | 12% |
| Student > Master | 18 | 12% |
| Student > Bachelor | 14 | 10% |
| Other | 19 | 13% |
| Unknown | 25 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 49 | 34% |
| Biochemistry, Genetics and Molecular Biology | 17 | 12% |
| Pharmacology, Toxicology and Pharmaceutical Science | 17 | 12% |
| Agricultural and Biological Sciences | 16 | 11% |
| Immunology and Microbiology | 3 | 2% |
| Other | 16 | 11% |
| Unknown | 27 | 19% |
Attention Score in Context
This research output has an Altmetric Attention Score of 543. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 May 2022.
All research outputs
#36,346
of 22,840,638 outputs
Outputs from Dermatology and Therapy
#2
of 804 outputs
Outputs of similar age
#540
of 392,776 outputs
Outputs of similar age from Dermatology and Therapy
#1
of 10 outputs
Altmetric has tracked 22,840,638 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 804 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.2. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 392,776 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them